# S&E bio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/s-e-bio-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.snebio.com
- Total disclosed funding: $9.7M
- Latest round: Series A (Dec 29, 2022)
- Investors on record: 7

## About

Based in South Korea, S&E bio Co., Ltd. focuses on developing innovative exosome-based therapies to address intractable diseases, enhancing treatment options for acute ischemic stroke and other neurological conditions. Founded in 2019 in Seoul, South Korea, S&E bio Co., Ltd. specializes in advancing cellular therapies, particularly exosome-based solutions. The company, led by CEO Oh-young Bang, has secured KRW 9.3 billion through its Series A funding round in December 2022 from Infobank, Samsung Life Public Welfare Foundation, LSK Investment, JW Pharmaceutical, Korea Investment Partners, KB Investment, and Company K Partners. This funding will support clinical trials and product development, including Evimir-Stroke. S&E bio Co., Ltd. excels in creating exosome-based therapies aimed at treating intractable diseases, with its primary product SNE-101 targeting acute ischemic stroke by promoting neurovascular regeneration while reducing oxidative stress and inflammation. The company serves hospitals and healthcare providers in South Korea, with plans to expand its offerings to broader Asian markets, focusing on innovative cell-free therapies for neurological conditions. S&E bio Co., Ltd. generates revenue through partnerships with healthcare institutions, integrating its exosome-based therapies into clinical practices post-approval. The company follows a B2B model, collaborating with hospitals to conduct clinical trials. Its pricing strategy reflects the innovative nature of its flagship product SNE-101, while ongoing research collaborations enhance the marketability of its therapies. With the most recent funding of KRW 9.3 billion raised in December 2022, S&E bio Co., Ltd. plans to initiate clinical trials for Evimir-Stroke, targeting acute stroke treatments. This strategic growth is aligned with the company's goal to penetrate new markets across Asia in the forthcoming years.

## Funding rounds

- Series A, Dec 29, 2022, $7.3M — KB Investment, Korea Investment Partners, Company K Partners, LSK Investment, Infobank, JW Pharmaceutical, Samsung Life Public Welfare Foundation
- Series A, May 6, 2020, $2.5M — KB Investment, Company K Partners

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A
- Infobank (https://capitalatlas.ai/funds/infobank) — Series A
- JW Pharmaceutical — Series A
- Samsung Life Public Welfare Foundation — Series A